Patents Assigned to Keros Therapeutics, Inc.
-
Patent number: 11912750Abstract: The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.Type: GrantFiled: November 9, 2017Date of Patent: February 27, 2024Assignee: Keros Therapeutics, Inc.Inventors: Jasbir S. Seehra, Jennifer Lachey
-
Patent number: 11884715Abstract: The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and/or pulmonary hypertension.Type: GrantFiled: July 9, 2020Date of Patent: January 30, 2024Assignee: Keros Therapeutics, Inc.Inventors: Jasbir S. Seehra, Jennifer Lachey
-
Patent number: 11717558Abstract: The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.Type: GrantFiled: May 24, 2021Date of Patent: August 8, 2023Assignee: Keros Therapeutics, Inc.Inventors: Jasbir S. Seehra, Jennifer Lachey
-
Patent number: 11484573Abstract: The invention features polypeptides that include an extracellular ActRlla variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRlla variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving bone damage, e.g., primary osteoporosis, secondary osteoporosis, osteopenia, osteopetrosis, fracture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.Type: GrantFiled: November 9, 2018Date of Patent: November 1, 2022Assignee: Keros Therapeutics, Inc.Inventors: Jennifer Lachey, Jasbir S. Seehra
-
Publication number: 20210275637Abstract: The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.Type: ApplicationFiled: May 24, 2021Publication date: September 9, 2021Applicants: Keros Therapeutics, Inc., Keros Therapeutics, Inc.Inventors: Jasbir S. SEEHRA, Jennifer LACHEY
-
Patent number: 11090361Abstract: The invention features polypeptides that include an extracellular ActRlla variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRlla variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving bone damage, e.g., primary osteoporosis, secondary osteoporosis, osteopenia, osteopetrosis, facture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.Type: GrantFiled: November 9, 2017Date of Patent: August 17, 2021Assignee: Keros Therapeutics, Inc.Inventors: Jasbir S. Seehra, Jennifer Lachey
-
Patent number: 11013785Abstract: The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.Type: GrantFiled: November 9, 2017Date of Patent: May 25, 2021Assignee: Keros Therapeutics, Inc.Inventors: Jasbir S. Seehra, Jennifer Lachey